Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKBIA | P25963 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EDNRA | P25101 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10888517 | 0.98 | NFKBIA (0.58) | NFKBIARELASLC40A1MEN1KMT2A | |
| SCHEMBL11269034 | 0.83 | SLC40A1 (0.49) | NFKBIARELASLC40A1MEN1KMT2A | |
| SCHEMBL2986277 | 0.83 | NPSR1 (0.65) | NFKBIARELASLC40A1MEN1KMT2A | |
| SCHEMBL2762847 | 0.83 | SMN1; SMN2 (0.62) | NFKBIARELASLC40A1MEN1KMT2A | |
| SCHEMBL11267055 | 0.80 | NFKBIA (0.45) | NFKBIARELASLC40A1MEN1KMT2A | |
| SCHEMBL10711350 | 0.80 | LMNA (0.62) | NFKBIARELASLC40A1MEN1KMT2A | |
| SCHEMBL11272841 | 0.80 | NFKBIA (0.48) | NFKBIARELASLC40A1MEN1KMT2A | |
| SCHEMBL8864437 | 0.79 | NFKBIA (0.51) | NFKBIARELASLC40A1MEN1KMT2A | |
| SCHEMBL1094168 | 0.79 | KDM4E (0.55) | SLC40A1MEN1KMT2ALMNAAURKA | |
| SCHEMBL11225975 | 0.78 | NFKBIA (0.49) | NFKBIARELASLC40A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4315931-A | MICROBIOCIDES, INFECTIOUS DISEASES | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | claimed |
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7553971-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1446379-B1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
| US-7125892-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060178410-A1 | Preparation of N-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-2-hydroxy-2-(3-hydroxymethyl-4-hydroxyphenyl)ethylamine, for example; for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-08-10 | — | — | US | disclosed |
| EP-1446379-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040063755-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-04-01 | — | — | US | disclosed |
| EP-0000335-B1 | ESTERS OF N-PYRIMIDINYL-CARBOXIMIDIC ACID, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM. | BASF Aktiengesellschaft (DE) | 1981-10-07 | — | — | EP | disclosed |
| EP-0000334-B1 | 2,4-DIAMINO-5-BENZYL-PYRIMIDINES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1981-08-12 | — | — | EP | disclosed |
| US-4279899-A | MICROBIOCIDES | BASF AKTIENGESELLSCHAFT (DE) | 1981-07-21 | — | — | US | disclosed |
| EP-0000336-B1 | N-BENZYLPYRIMIDINYL-AMIDINES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1981-04-15 | — | — | EP | disclosed |
| EP-0017772-A1 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-10-29 | — | — | EP | disclosed |
| EP-0014263-A2 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
| US-4189581-A | BACTERICIDES, POTENTIATORS OF SULFA DRUGS | BASF AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
| EP-0000335-A1 | Esters of N-pyrimidinyl-carboximidic acid, process for their preparation and medicines containing them. | BASF Aktiengesellschaft (DE) | 1979-01-24 | — | — | EP | disclosed |
| EP-0000336-A1 | N-benzylpyrimidinyl-amidines, process for their preparation and medicines containing them | BASF Aktiengesellschaft (DE) | 1979-01-24 | — | — | EP | disclosed |
| EP-0000334-A1 | 2,4-Diamino-5-benzyl-pyrimidines, process for their preparation and medicines containing them | BASF Aktiengesellschaft (DE) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | NFKBIA 3386/4885RELA 3849/4885SLC40A1 4105/4885 |
| US-20040063755-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | NFKBIA 3598/4885RELA 4345/4885SLC40A1 4000/4885 |
| US-20060178410-A1 | Preparation of N-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-2-hydroxy-2-(3-hydroxymethyl-4-hydroxyphenyl)ethylamine, for example; for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease | ADRB2, ADRB3, ADRA2C | NFKBIA 2199/4885RELA 2987/4885SLC40A1 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.